Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 In vitro activities of doripenem and comparator agents against 364 anaerobic clinical isolates.

Literature DB >> 16189137

In vitro activities of doripenem and comparator agents against 364 anaerobic clinical isolates.

Hannah M Wexler¹, Adrian E Engel, Daniel Glass, Calida Li.

Abstract

The in vitro activities of doripenem against 364 anaerobic isolates were measured and compared to those of ertapenem, imipenem, meropenem, ceftriaxone, and levofloxacin. All of the carbapenems were active against nearly all Bacteroides fragilis group isolates. Doripenem was either comparable to or slightly less active than imipenem and meropenem against most isolates but more active than the other penems against Clostridium difficile. Doripenem appears to have excellent activity against a broad range of anaerobes.

Entities: Chemical Species

Mesh：

Substances：

Year: 2005 PMID： 16189137 PMCID： PMC1251538 DOI： 10.1128/AAC.49.10.4413-4417.2005

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

18 in total

1. Comparative in vitro activity of S-4661, a new parenteral carbapenem, and other antimicrobial agents against respiratory pathogens.

Authors: A Watanabe; H Takahashi; T Kikuchi; T Kobayashi; K Gomi; S Fujimura; Y Tokue; T Nukiwa
Journal: Chemotherapy Date: 2000 May-Jun Impact factor: 2.544

2. In vitro antibacterial activity of S-4661, a new parenteral carbapenem, against urological pathogens isolated from patients with complicated urinary tract infections.

Authors: S Nomura; A Nagayama
Journal: J Chemother Date: 2002-04 Impact factor: 1.714

3. Comparative In vitro activities of ertapenem (MK-0826) against 1,001 anaerobes isolated from human intra-abdominal infections.

Authors: E J Goldstein; D M Citron; C Vreni Merriam; Y Warren; K L Tyrrell
Journal: Antimicrob Agents Chemother Date: 2000-09 Impact factor: 5.191

4. A silent carbapenemase gene in strains of Bacteroides fragilis can be expressed after a one-step mutation.

Authors: I Podglajen; J Breuil; F Bordon; L Gutmann; E Collatz
Journal: FEMS Microbiol Lett Date: 1992-02-01 Impact factor: 2.742

5. Comparison of spiral gradient and conventional agar dilution for susceptibility testing of anaerobic bacteria.

Authors: H M Wexler; E Molitoris; F Jashnian; S M Finegold
Journal: Antimicrob Agents Chemother Date: 1991-06 Impact factor: 5.191

6. Expression of the carbapenemase gene (cfiA) in Bacteroides fragilis.

Authors: R Edwards; P N Read
Journal: J Antimicrob Chemother Date: 2000-12 Impact factor: 5.790

7. Pseudomonas aeruginosa reveals high intrinsic resistance to penem antibiotics: penem resistance mechanisms and their interplay.

Authors: K Okamoto; N Gotoh; T Nishino
Journal: Antimicrob Agents Chemother Date: 2001-07 Impact factor: 5.191

8. In vitro and in vivo antibacterial activities of a new injectable carbapenem, S-4661, against gynaecological pathogens.

Authors: H Mikamo; K Izumi; Y X Hua; Y Hayasaki; Y Sato; T Tamaya
Journal: J Antimicrob Chemother Date: 2000-09 Impact factor: 5.790

9. In vitro and in vivo antibacterial activities of S-4661, a new carbapenem.

Authors: M Tsuji; Y Ishii; A Ohno; S Miyazaki; K Yamaguchi
Journal: Antimicrob Agents Chemother Date: 1998-01 Impact factor: 5.191

10. Antimicrobial susceptibility testing of Bilophila wadsworthia by using triphenyltetrazolium chloride to facilitate endpoint determination.

Authors: P Summanen; H M Wexler; S M Finegold
Journal: Antimicrob Agents Chemother Date: 1992-08 Impact factor: 5.191

13 in total

1. Activity of doripenem against extended-spectrum beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa isolates.

Authors: C Betriu; M Gómez; F López-Fabal; E Culebras; I Rodríguez-Avial; J J Picazo
Journal: Eur J Clin Microbiol Infect Dis Date: 2010-06-04 Impact factor: 3.267

2. Population Pharmacokinetic Analysis of Doripenem after Intravenous Infusion in Korean Patients with Acute Infections.

Authors: Dong-Hwan Lee; Yong Kyun Kim; Kyubok Jin; Myoung Joo Kang; Young-Don Joo; Yang Wook Kim; Young Soo Moon; Jae-Gook Shin; Sungmin Kiem
Journal: Antimicrob Agents Chemother Date: 2017-04-24 Impact factor: 5.191

Review 3. Comparative review of the carbapenems.

Authors: George G Zhanel; Ryan Wiebe; Leanne Dilay; Kristjan Thomson; Ethan Rubinstein; Daryl J Hoban; Ayman M Noreddin; James A Karlowsky
Journal: Drugs Date: 2007 Impact factor: 9.546

4. Doripenem (Doribax): the newest addition to the carbapenems.

Authors: Nickie D Greer
Journal: Proc (Bayl Univ Med Cent) Date: 2008-07

5. In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.

Authors: Ellie J C Goldstein; Diane M Citron; C Vreni Merriam; Yumi A Warren; Kerin L Tyrrell; Helen T Fernandez
Journal: Antimicrob Agents Chemother Date: 2007-12-10 Impact factor: 5.191

6. In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.

Authors: David R Snydman; Nilda V Jacobus; Laura A McDermott
Journal: Antimicrob Agents Chemother Date: 2008-10-06 Impact factor: 5.191

7. In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004.

Authors: David W Hecht; Minerva A Galang; Susan P Sambol; James R Osmolski; Stuart Johnson; Dale N Gerding
Journal: Antimicrob Agents Chemother Date: 2007-05-21 Impact factor: 5.191